Ad
related to: anti tuberculosis drug
Search results
Oxford Nanopore Technologies Eyes TB Test as First In-House-Developed Diagnostic Test
GenomeWeb News· 5 hours agoOxford Nanopore Technologies has been working on a tuberculosis drug resistance sequencing assay that it hopes will become its first in vitro diagnostic ...
Antibiotic resistance causing large avoidable death toll, doctors say
dpa international via Yahoo News· 41 minutes agoAround 750,000 of the almost 5 million annual deaths caused by antimicrobial resistance - when...
Delhi HC closes PIL on medicine shortage in Rajan Babu Institute after govt's assurance
Investing.com· 20 hours agoThe decision came after a division bench of Acting Chief Justice Manmohan and Justice Manmeet PS...
Over 750,000 antimicrobial resistance deaths preventable yearly via vaccines, water, sanitation and...
Medical Xpress· 2 hours agoAuthors say if the world does not prioritize action on AMR now, we will see a steady increase in the...
Celltrion USA announces two-year data for ZYMFENTRA™(infliximab-dyyb) to be presented at Digestive...
FOX 5 San Diego· 7 days agoCelltrion USA today announced it will present the two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) in adult patients with moderately to severely active Crohn's ...
Teva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.
Morningstar· 3 days agoTeva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO),today announced the availability of SIMLANDI (adalimumab-ryvk) ...
How biologics can help with symptoms of Crohn's
Medical News Today· 6 days agoBiologic therapies for Crohn’s disease (CD) do more than reduce the common symptoms of diarrhea, abdominal cramping, and pain. CD and ulcerative colitis...
MedPod Today: RFK Jr.'s Ailments; Tenpenny Gets License Back; Shady Stem Cell Shots
MedPage Today· 7 days agoThen Kristina Fiore tells us about how the doctor who said that the COVID vaccine can magnetize...
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in...
WPRI Providence· 14 hours agoUCB, a global biopharmaceutical company, today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX ...
More than one-half of patients with Crohn's disease treated with Lilly's mirikizumab achieved...
WTRF Wheeling· 3 days agoIn Eli Lilly and Company's (NYSE: LLY) pivotal Phase 3 VIVID-1 study, patients with moderately to severely active Crohn's disease, with or without previous biologic failure, achieved statistically ...